ЮРАК ИШЕМИК КАСАЛЛИГИНИ БАШОРАТ ҚИЛИШ УЧУН ТЎҚЛИК ВА ОЧЛИКДА ТРИГЛИЦЕРИДЛАРНИНГ ОПТИМАЛ ЧЕГАРА НУҚТАЛАРИ: ЮРАК ҚОН-ТОМИР ХАВФИНИ ЎРГАНИШ
##article.subject##:
Триглицеридлар, оптимал кесиш нуқтаси, юрак ишемик касаллиги, умумий популяция, когорт тадқиқоти##article.abstract##
Тўқлик ва очлик учун оптимал чегара нуқталари 145 мг/дл ва 110 мг/дл бўлиб, C-статистик 0,594 ва 0,626, Youden индекси 0,187 ва 0.252 ва Harrell нинг мувофиқлик статистикаси 0,590 ва 0,630. Юрак ишемик касаллигининг мос келадиган кўп ўзгарувчан хавф нисбати 1,43 (95% ИО 1,09-1,88) ва 1,69 (1,03-2,77) ва мос келадиган популяция фракциялари 16,1% (95% ИО 3,3-27,2%) ва оптимал нуқта (24,3-3,6 нуқта) эди. Бухоронинг умумий популяциясидаги очлик ва очлик триглицеридларининг даражаси мос равишда 145 мг/дл ва 110 мг/дл ни ташкил этди.
Библиографические ссылки
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, and Yeboah J: 2018
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation, 2019; 139: e1082-e1143
Tada H, Takamura M, and Kawashiri MA: Triglycerides on the Rise J Atheroscler Thromb, 2021; 28: 1263-1265
Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, Shimamoto T, Iida M, and Komachi Y: Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol, 2001; 153: 490-499
Yamagishi K, Iso H, Sairenchi T, Irie F, Takizawa N, Koba A, Tomizawa T, and Ota H: Diabetes mellitus modifies the association of serum triglycerides with ischemic cardiovascular disease mortality: The Ibaraki Prefectural Health Study (IPHS). J Atheroscler Thromb, 2021, online ahead of print. DOI: 10.5551/jat.63081
Higashiyama A, Wakabahashi I, Okamura T, Kokubo Y, Watanabe M, Takegami M, Honda-Kohmo K, Okahama A, and Miyamoto Y: The risk of fasting triglycerides and its related indices for ischemic cardiovascular diseases in Japanese community dwellers: the Suita Study. J Atheroscler Thromb, 2021; 28: 1275-1288
Iso H, Imano H, Yamagishi K, Ohira T, Cui R, Noda H, Sato S, Kiyama M, Okada T, Hitsumoto S, Tanigawa T, Kitamura A, and CIRCS Investigators: Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Atherosclerosis, 2014; 237: 361-368
Nordestgaard BG: A Test in Context: lipid profile, fasting versus nonfasting. J Am Coll Cardiol, 2017; 70: 1637-1646
Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, and Ridker PM: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA, 2007; 298: 309-316
Mora S, Rifai N, Buring JE, and Ridker PM: Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation, 2008; 118: 993-1001
Langsted A, Freiberg JJ, and Nordestgaard BG: Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation, 2008; 118: 2047-2056
Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, and Nordestgaard BG: Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA, 2008; 300: 2142-2152
Langsted A, Freiberg JJ, Tybjaerg-Hansen A, Schnohr P, Jensen GB, and Nordestgaard BG: Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med, 2011; 270: 65-75
Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, and Nordestgaard BG: Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol, 2013; 61: 427-436
Nordestgaard BG, Hilsted L, Stender S: Plasma lipids in non-fasting patients and signal values of laboratoryresults. Ugeskr Laeger, 2009; 171: 1093
Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S; American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease: Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 2011; 123: 2292-2333
Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Downs JR, O’Malley PG. Ann Intern Med, 2015; 163: 291-297
NICE Guidance. Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE. Updated 2016. Available at: https: //www.nice.org.uk/guidance/cg181
White KT, Moorthy MV, Akinkuolie AO, Demler O, Ridker PM, Cook NR, and Mora S: Identifying an optimal cutpoint for the diagnosis of hypertriglyceridemia in the nonfasting state. Clin Chem, 2015; 61: 1156-1163
